ClinicalTrials.gg
RecruitingNCT05566392Updated Aug 6, 2024

Longterm Influence of Pediatric Long COVID Syndrome

An observational study in COVID-19-Associated Encephalitis and Long COVID, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 6 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by National Taiwan University Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
500
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan — 5 open to participants now, 5 under way, none of them phase 3. Post-Acute COVID-19 Syndrome · Taiwan.

Started
2022
with 5 others
Observational
4 of 15
3 open now
Registered
2nd of 15
by date
Lead sponsor
2 of 15
National Taiwan University Hospital

Among the 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan, this one is one of 6 that started in 2022, is one of 4 observational ones, and was the 2nd registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

5 of the 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan, or all of them as a file.
02

Study summary

We enroll pediatric patients who were diagnosed COVID-19 for main observation target. We will perform brain MRI and neuropsychiatric evaluation 4-6 months after COVID-19 diagnosed. We also enroll healthy age- and gender-matched participant for cross-over comparison. We will perform same evaluation process one year later for longitudinal evaluation

03

Conditions studied

  • COVID-19-Associated Encephalitis
  • Long COVID

Keywords

  • pediatric neurology
  • psychiatric evaluation
  • Long COVID syndrome
  • magnetic resonance image
04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Aged between 6-18 years old pediatric patient diagnosed as COVID would be enrolled. The patient who had neuropsychiatric disorders would be excluded. We also enroll age- and gender-matched healthy participants for cross-over comparison

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 6-18 years old
  • Has been diagnosed COVID-19 before

Exclusion criteria

Exclusion Criteria:

  • History of neuropsychiatric disorders
  • Have some device not allowed for MRI
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Coronavirus disease (COVID)

    Pediatric patients who was diagnosed as COVID

    Diagnostic Test: Brain MRI

  • Healthy

    Pediatric participants who hadn't been diagnosed COVID before

    Diagnostic Test: Brain MRI

Interventions

  • Diagnostic testBrain MRI

    Brain MRI including diffusion spectrum image, and functional MRI Interview with questionnaires for neuropsychiatric evaluation Near infrared spectroscopy and resting-state connectivity evaluation

    Also known as: Neuropsychiatric evaluation, Near infrared spectroscopy

06

What researchers measure

Primary outcomes

  1. Difference between COVID and healthy group

    The neuroimage difference between COVID and healthy group and the correlation with neuropsychiatric evaluation

    Time frame: 1 years after enrollment for primary evaluation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — according to our participant consent, the participant information will be stored as de-identification data

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Oct 2025, 36 months after the start.

Of 97 non-industry observational studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's planned 36 months is above that.

Counting every sponsor, half of 104 studies reached it within 26 months; a quarter within 14 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2022
First posted
Oct 4, 2022
StartActual
Oct 20, 2022
Primary completionEst.
Oct 2025
CompletionEst.
Dec 2030
Last update
Aug 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05566392
Responsible party
Sponsor
First posted
Oct 4, 2022
Start date
Oct 20, 2022
Primary completion
Oct 2025 (estimated)
Completion
Dec 2030 (estimated)
Last update
Aug 6, 2024

Study contacts

Wang-Tso Lee, PHD
Contact
leeped@hotmail.com
(886)2-23123456 ext. 71618
Wang-Tso Lee, PHD
principal investigator · National Taiwan University Children Hospital Pediatric neurology department

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion